A Phase 1 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Trial Profile

A Phase 1 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Apr 2018

At a glance

  • Drugs Gilteritinib (Primary) ; Cytarabine; Idarubicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 02 Mar 2018 Planned number of patients changed from 44 to 70.
    • 12 Dec 2017 Preliminary results (n=50; as of 9 Jul 2017) assessing safety/tolerability and antitumor activity of gilteritinib in combination with front-line intensive chemotherapy, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 11 Dec 2017 According to an Astellas Pharma media release, as of July 9, 2017, 50 patients have been enrolled in the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top